GLP-1 for Obstructive Sleep Apnea

In obstructive sleep apnea the upper airway keeps collapsing during sleep, so breathing stops briefly and you surface again — over and over, often without remembering any of it. Severity is counted as events per hour: 5 to 14 is mild, 15 to 29 moderate, 30 or more severe. Left untreated it fragments sleep, drags on daytime alertness and thinking, and pushes up the risk of hypertension, an irregular heartbeat, heart attack, stroke and diabetes.

Nothing else modifiable matters as much as body fat. Tissue around the neck, tongue and airway narrows the passage and weakens the muscle tone holding it open, while fat around the middle restricts the chest wall and reduces the lung volume that would otherwise keep the airway tethered. A global analysis put around 936 million adults aged 30 to 69 as having some degree of it, with roughly 425 million in the moderate-to-severe range [4]. Population surveys have tracked its prevalence rising alongside obesity for decades [5].

Positive airway pressure remains first-line for moderate-to-severe disease, and its central weakness is that a great many people will not wear a mask every night. For years the alternatives — positional therapy, oral appliances, airway surgery — worked around the problem without touching what caused it. That changed in 2024, when tirzepatide became the first drug the FDA approved specifically to treat moderate-to-severe sleep apnea in adults with obesity.

The idea that shrinking airway fat could treat the disorder was first tested properly in the SCALE Sleep Apnea trial [3]. Adults with obesity and moderate-to-severe disease, none using a machine, were randomized for 32 weeks. Liraglutide 3.0 mg cut events by an average of 12.2 an hour against 6.1 on placebo — a treatment difference of 6.1 events an hour. Weight fell 5.7% against 1.6%. A post-hoc look confirmed the size of the weight loss tracked the size of the improvement, which is the finding that made the mechanism credible.

Confirmation arrived with SURMOUNT-OSA, two phase 3 randomized trials published in October 2024 [1]. One enrolled people not using a machine, the other people who were; both ran 52 weeks against placebo at the maximum tolerated tirzepatide dose. Starting severity was high — around 51.5 and 49.5 events an hour. In the first trial events fell by 25.3 an hour against 5.3 on placebo; in the second, by 29.3 against 5.5. In proportional terms that is a reduction of roughly a half and three-fifths from baseline.

The gains ran well past the headline count. Both trials showed improvement in hypoxic burden — how much oxygen deprivation accumulates across a night — and in reported sleep disturbance, in inflammatory markers, and in the upper blood pressure number [1]. A 2026 secondary analysis characterized those cardiometabolic improvements in more detail, documenting changes in inflammation, blood pressure and metabolic measures that matter for cardiovascular risk in their own right [2]. Some of that follows from treating the apnea; some is simply what this drug class does.

Those results produced the December 2024 approval of tirzepatide for moderate-to-severe sleep apnea in adults with obesity — the first time any drug had been approved for the condition as a primary indication rather than for its daytime consequences. Several mechanisms plausibly contribute: less fat around the airway, lower systemic inflammation, better respiratory muscle tone, and reduced overnight fluid shifts. Whether there is also a direct effect on respiratory control, beyond the fat loss, is still open.

The approval covers adults with moderate-to-severe disease — 15 or more events an hour — who also have obesity, meaning a BMI of 30 and over, or 27 alongside a weight-related condition. It is licensed as an adjunct to reduced calories and more activity, and can be used with or without a machine. It is not approved for sleep apnea in someone without obesity, and the diagnosis needs confirming by a sleep study or a validated home test first.

People already using a machine successfully can still be candidates, which is what the second trial was designed to show — the question there is added control and lower cardiometabolic risk rather than replacing the device. The drug is arguably more compelling for those who have refused or abandoned a machine, since treating the underlying obesity reduces severity whether or not a device is worn. Either way, reassess severity after meaningful weight loss, usually 10 to 15%, to see whether pressure settings need changing.

Mild disease, at 5 to 14 events an hour, sits outside the approved indication, though weight loss in that group frequently resolves the problem outright. At the severe end, with class II or III obesity, bariatric surgery remains an alternative or an addition and produces larger, more durable reductions. Choosing between them turns on other conditions, symptom burden, appetite for an invasive option, and whether surgical expertise is actually available to you.

Stomach side effects are the common ones and cluster during escalation — nausea, vomiting, diarrhea, constipation. In the trials they were mostly mild to moderate and did not drive high dropout. The standard schedule takes twenty weeks or more to reach the maximum tolerated dose for exactly this reason, and taking the injection with food helps. Expect them to be temporary rather than reading them as a reason to stop.

This does not replace a machine for someone with severe or symptomatic disease who is using one successfully. The two do different jobs on different timescales: the device handles oxygenation tonight, the drug addresses the cause across months. Nobody should stop their machine in anticipation of improvement — only after a repeat sleep study, done once weight has stabilized, shows the apnea is genuinely controlled without it.

The class contraindications apply here as everywhere: no one whose own or family history includes medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Inflamed pancreas, gallbladder trouble and sudden kidney injury are all uncommon and all real. What a plan pays against a sleep apnea indication is not necessarily what it pays for weight management, and authorization rules differ between payers, so check which one your approval is written against. And the apnea can return if weight does, which makes staying on it part of the treatment rather than an afterthought.